Trials / Recruiting
RecruitingNCT07038005
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SPGL008 Monotherapy for Patients With Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.
Detailed description
This study is a study of SPGL-008 monotherapy in patients with advanced malignant tumors. The study includes two cohorts, Cohort 1 and Cohort 2 will be administered by intravenous and subcutaneous administration respectively. Both cohorts will be conducted by the dose-escalation design to evaluate safety, tolerability and preliminary efficacy of different administration of SPGL008.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPGL008 | Biological product |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2026-09-22
- Completion
- 2027-06-08
- First posted
- 2025-06-26
- Last updated
- 2026-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07038005. Inclusion in this directory is not an endorsement.